2013 Biosimilars Insurance Coverage and Processing 
Express Pharma
MARCH 16, 2025
On the global stage, AI and Machine Learning (ML) drove drug discovery and process optimisation, especially as large-scale pharma companies adopted AI for precision medicine. Building sophisticated laboratories, recruiting scientific talent, and collaborating with global research institutions are essential steps in this process.
Pharmacy Times
AUGUST 11, 2025
Most MTM platforms use health plan adjudication data, allowing pharmacists to see any medication billed through the patient’s insurance, even if it was not filled at their pharmacy. Quality of care transition, patient safety incidents, and patients’ health status: a structural equation model on the complexity of the discharge process.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaShots
JUNE 28, 2023
The co-promotion collaboration agreement between the two companies in the United States and Canada expired on October 31, 2013. Some of the alternative drugs for Enbrel include: Enbrel’s Biosimilars6 As Enbrel has a long journey in the market it is already facing competition from biosimilars in the US and other countries.
Pharmaceutical Commerce
JUNE 13, 2025
Those patients would lose insurance coverage/access to those products, but the PBM was contractually obligated to keep the product on formulary for the other 85% of lives. The loophole I just described was what he used to process that increase. Some companies saw this as a winning commercial decision. to $750 per pill.
Expert insights. Personalized for you.
Let's personalize your content